And further, whenever anyone turns up to say "metformin is great", just point them at the studies showing that aspirin does a fair job of extending healthy life

And further, whenever anyone turns up to say "metformin is great", just point them at the studies showing that aspirin does a fair job of extending healthy life span in a variety of laboratory species. Arguably the aspirin life span studies show more consistent results than metformin, though there are fewer of them. And we all know what aspirin does for human life span. For senolytic therapies, look at Unity Biotechnology's pharmaceutical trials starting this year, Oisin Biotechnologies' gene therapy approach, SIWA Therapeutics with an antibody approach. There are a dozen or so candidate drugs worth looking at, in addition to the non-drug approaches. If you have the connections you can order any of the various senolytic pharmaceuticals today and try them. Though this would be unwise for the chemotherapeutics with animal data, since they are not friendly compounds, and worth waiting for a year or two to see how more targeted things like FOXO4-DRI work out in human tests. A year or two from now will be a great time for self-experimentation on this front, given the range of candidates and the size of the effects in mice where there is data. Today the situation is in an awkward state where some of the easier pharmaceuticals to handle are either going to have tiny effects or have no animal data, while the others still need human data. Still, I would expect medical tourism to flourish for these things quite soon: the drugs are cheap, the beneficial effects sizable.